Canaccord raises Tandem Diabetes Care target to $59

On Thursday, Canaccord Genuity adjusted its price target for Tandem Diabetes Care (NASDAQ:TNDM) shares, increasing it to $59 from the previous $58, while maintaining a Buy rating on the stock. The firm’s analysts highlighted Tandem’s strong performance in the first quarter, noting a revenue of $234.4 million, which represents an approximate 22% year-over-year increase. This figure surpassed both Canaccord Genuity’s and consensus estimates, propelled by robust supplies revenue in both the U.S. and international markets. The performance was slightly tempered by lower-than-anticipated pump revenue. According to InvestingPro data, TNDM has maintained impressive revenue growth with a 5-year CAGR of 21%, though the stock is currently trading near its 52-week low of $15.75.

Tandem Diabetes Care’s management has confirmed its financial guidance, a move interpreted by Canaccord Genuity as indicative of a cautious approach to forecasting in the current economic climate. Despite this caution, the company does not foresee significant impacts from tariffs on its gross margins. Looking ahead, Tandem has shared updates on its product pipeline, including the anticipated Q2/25 integration of its t:slim X2 with Abbott’s Libre 3 Plus and subsequent Mobi integration. Additionally, the Mobi product is under review for CE Mark certification, with an expected launch in international markets in the second half of 2025. InvestingPro analysis reveals the company maintains a strong liquidity position with a current ratio of 2.93, suggesting ample resources to fund its product development initiatives.

The analysts at Canaccord Genuity expressed optimism about Tandem’s future, particularly noting the potential for gross margin improvement. Management has projected that the company could achieve a 60% gross margin in 2026, attributing this to several factors such as the gross margin accretion from Mobi, increased pharmacy pricing, and higher revenue and average selling price from the shift to direct international sales. Current gross profit margin stands at 52.07%, according to InvestingPro data, which also indicates the company operates with a moderate level of debt and maintains a Fair overall financial health score.

The report also addresses concerns that arose from the restructuring of the U.S. salesforce earlier in the year, which had a negative impact on the stock. Canaccord Genuity believes that Tandem is well-positioned for growth due to its extensive product offerings, the opportunity presented by the type 2 diabetes market, potential for margin expansion, and increasing free cash flow. The firm also pointed out the company’s current valuation, which stands at approximately 1.0 times its projected 2026 enterprise value to sales ratio, as a compelling reason for their Buy rating and updated price target. Based on InvestingPro’s Fair Value analysis, TNDM appears undervalued at its current market price of $16.85. For deeper insights into TNDM’s valuation and growth prospects, including access to comprehensive financial metrics and expert analysis, explore the full research report available on InvestingPro.

In other recent news, Tandem Diabetes Care disclosed its Q1 2025 earnings, which revealed an earnings per share (EPS) of -1.97, significantly missing the forecast of -0.6. However, the company reported a revenue of $234 million, which exceeded expectations and reflected a 22% year-over-year growth. This growth was largely driven by a 35% increase in international sales and a 15% rise in U.S. sales. Despite the EPS miss, the company’s stock saw an increase, possibly due to investor optimism about Tandem’s strategic product developments and international market expansion. Tandem Diabetes Care is targeting a gross margin of 54% in 2025 and aims to return to positive free cash flow in the second half of the year. Analyst firms such as Barclays (LON:BARC) and Stifel have shown interest in the company’s strategic initiatives, including the expansion of its pharmacy channel and new product launches. The company remains focused on its worldwide sales projection between $997 million and $1 billion for 2025. Additionally, Tandem has received FDA clearance for its Control IQ Plus, which is expected to significantly impact its market reach.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.